UK markets close in 1 hour 33 minutes
  • FTSE 100

    6,709.22
    -11.43 (-0.17%)
     
  • FTSE 250

    20,612.57
    -26.77 (-0.13%)
     
  • AIM

    1,177.15
    +2.88 (+0.25%)
     
  • GBP/EUR

    1.1219
    -0.0026 (-0.23%)
     
  • GBP/USD

    1.3612
    +0.0025 (+0.19%)
     
  • BTC-GBP

    27,243.64
    +414.18 (+1.54%)
     
  • CMC Crypto 200

    735.02
    +19.83 (+2.77%)
     
  • S&P 500

    3,785.21
    +16.96 (+0.45%)
     
  • DOW

    30,914.86
    +100.60 (+0.33%)
     
  • CRUDE OIL

    52.80
    +0.44 (+0.84%)
     
  • GOLD FUTURES

    1,839.60
    +9.70 (+0.53%)
     
  • NIKKEI 225

    28,633.46
    +391.25 (+1.39%)
     
  • HANG SENG

    29,642.28
    +779.51 (+2.70%)
     
  • DAX

    13,846.97
    -1.38 (-0.01%)
     
  • CAC 40

    5,605.11
    -12.16 (-0.22%)
     

Anti-CD19 Antibody Pipeline Insight 2020, Featuring Marino Biotechnology, Xencor, ImmunoGen, MedImmune and Merck KGaA

Research and Markets
·3-min read

Dublin, Nov. 26, 2020 (GLOBE NEWSWIRE) -- The "Anti-CD19 Antibody - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides a detailed picture of the Anti-CD19 Antibody pipeline landscape.

The assessment part of the report embraces, in-depth Anti-CD19 Antibody commercial assessment and clinical assessment of the pipeline products under development. In the report, a detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All the companies developing therapies of Anti-CD19 Antibody with aggregate therapies developed by each company for the same.

  • Different therapeutic candidates in early-stage, mid-stage and late stage of development for Anti-CD19 Antibody.

  • Key players involved in Anti-CD19 Antibody targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future developments of Anti-CD19 Antibody.

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises collaborations, licensing, acquisition deal value trends. The sub-segmentation is described in the report, which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.

Scope of the Report

  • The Anti-CD19 Antibody report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and non-clinical stages.

  • It comprises of detailed profiles of Anti-CD19 Antibody therapeutic products with key coverage of involved technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

  • Elucidated Anti-CD19 Antibody research and development progress and trial details, results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Anti-CD19 Antibody.

Report Highlights

  • In the coming years, the Anti-CD19 Antibody market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

  • The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD19 Antibody R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • There are several companies involved in developing therapies for Anti-CD19 Antibody. Launch of emerging therapies of Anti-CD19 Antibody will significantly impact the market.

  • A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Anti-CD19 Antibody.

  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Anti-CD19 Antibody) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Companies Mentioned

  • Marino Biotechnology

  • Xencor

  • ImmunoGen

  • MedImmune

  • Merck KGaA

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ov2o7m

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900